Sight Sciences

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Sight Sciences sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 9 completed later-stage tilt top decile by trial count

Sight Sciences: 14 sponsored US clinical trials, none currently recruiting.

Sight Sciences sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye, with 1 trials.

Top-decile sponsor footprint

Sight Sciences ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

9 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (64.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

COMPLETED NA

TearCare MGX™ System With and Without Warming Hold

NCT07365735
TERMINATED Phase 4

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
COMPLETED

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

NCT05044793
COMPLETED

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

NCT04872348
COMPLETED NA

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

NCT04795752
TERMINATED NA

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

NCT04616573
TERMINATED NA

A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma

NCT04465630
COMPLETED NA

Study of OMNI System in OAG (GEMINI)

NCT03861169
COMPLETED NA

TearCare System to Treat Dry Eye Disease

NCT03857919
COMPLETED NA

Pilot Study of TearCare System - Long-Term Extension

NCT03804502
COMPLETED NA

Study of the TearCare System in Dry Eye Disease

NCT03588624
TERMINATED NA

Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease

NCT03502447
TERMINATED NA

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

NCT02928289
COMPLETED NA

A Pilot Study of the TearCare System in Adults With Dry Eye Disease

NCT03006978

Phase Distribution

PhaseTrial count
Phase 4 1

Therapeutic Areas

Dry Eye 1
Glaucoma Open-Angle 1

How the Sight Sciences archive is shaped

14 indexed studies, none listed as recruiting (0% open); 9 completed (64%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Dry Eye (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Sight Sciences: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Sight Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Sight Sciences3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Sight Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sight Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sight Sciences page

14 registered trials is a research-attention snapshot, not an endorsement of Sight Sciences or any single study.

  • None of Sight Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dry Eye is the condition Sight Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sight Sciences pipeline card: 14 registered trials from official public datasets.Report a data error.